Clinical

Barriers inhibiting optimal CKD treatment for patients are underlined.

During ESMO Congress 2023, sessions will focus on hot topics in therapeutic areas, such as the use of immunotherapies in both the neoadjuvant and adjuvant settings, as well as nontherapeutic topics, such as the needs of caregivers and advances in technology.

The results for a proposed aflibercept (Eylea) biosimilar and an accepted ranibizumab (Lucentis) biosimilar were presented at Euretina Congress 2023.

The anti–PD-1 agent pembrolizumab was granted a new indication to treat patients with resectable non–small cell lung cancer (NSCLC) as a neoadjuvant treatment with chemotherapy and continued as adjuvant treatment after surgery.

The marketing denial orders were due to what the FDA stated as insufficient data supporting the products' additional benefit for adults switching from smoking cigarettes to vaping or cessation.

Non–guideline-concordant care for ovarian cancer was associated with higher all-cause and cancer-specific mortality, increased health care utilization, and increased Medicare expenditures, highlighting opportunities for improving cancer care in this vulnerable group.

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.

Ghassan Abou-Alfa, MD, MBA, and Mohamed Salem, MD, provide insights regarding potential clinical pathway-driven challenges associated with HCC management.

A panel of medical experts open a discussion surrounding key treatment strategies in management of hepatocellular carcinoma (HCC).

Investigators evaluated 70 patients in a retrospective study.

Crinetics announced findings from the PATHFNDR-1 trial showing the investigative oral daily drug may provide patients with the rare disease an alternative from recurring injection therapy.

Pembrolizumab plus chemotherapy prior to surgery, followed by resection and single-agent pembrolizumab in the adjuvant setting, significantly improved overall survival (OS) vs neoadjuvant placebo plus chemotherapy followed by adjuvant placebo in patients with resectable stage II, IIIA, or IIIB (T3-4N2) non–small cell lung cancer, meeting the dual primary end point of the phase 3 KEYNOTE-671 trial.

Results show engaging in unstructured physical activities, even those of low intensity and carried out in the morning and early afternoon, is linked to reduced average glucose levels throughout the day and night.

Age, fecal calprotectin level, toxin B polymerase chain reaction cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent Clostridioides difficile infection.

This new data represents the first real-world, US-based data on this drug, demonstrating the efficacy and the safety indications of these clinical trials.

A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.

In his final thoughts, Dr Gerds discusses emerging therapies for the treatment of PV.

Uncontrolled PV is highlighted by a key opinion leader.

Treatment of DLBCL amid comorbidities in elderly patients is highlighted.

Dr Gordon discusses use of bispecifics for management of patients with relapsing DLBCL.

Patients with paroxysmal nocturnal hemoglobinuria (PNH) had decreased quality of life (QOL) and worse fatigue that could be linked to lactate dehydrogenase levels.

At week 52, sustained remission was observed in significantly more patients receiving sarilumab compared with placebo.

Positive results from STEP-HFpEF indicate that semaglutide can improve quality of life and functional capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF), but large outcomes trials are needed to confirm this, said Javed Butler, MD, MPH, MBA.

Knowledge of the different treatment options available and the eligibility criteria for each will help identify the right treatment for patients with hepatobiliary cancer.

Medicare Part A and B premiums are set to increase by $9.80 next year; 20 experts from various specialties and institutions have developed updated brain death guidelines; many Black patients are strongly affected by multiple COVID-19 infections due to a lack of health insurance and health care access.

The researchers explained that little is known about how primary care providers should handle atopic dermatitis (AD) cases and whether they should follow national recommendations.

Elevated white blood cell counts also appear to correlate with shorter overall survival in patients receiving standard induction chemotherapy plus cytarabine for acute myeloid leukemia.

The preoperative risk assessment algorithm can identify ovarian lesions with a strong likelihood of being non-cancerous and suitable for ovary-preserving surgery.